PubMed Health⌕ Search

Biomedical subjects

H D'haenen

Publications and source records attributed to H D'haenen.

8 recordsLinked to original sources
PubMed2005

Lack of impact of repetitive High Frequency Transcranial Magnetic Stimulation on mood in healthy female subjects.

BACKGROUND: High Frequency repetitive Transcranial Magnetic Stimulation (HF-rTMS) is currently used as an experimental tool to induce mood changes in normal volunteers and as a treatment option for depression. However, HF-rTMS, mostly performed on the left dorsolateral prefrontal cortex (DLPFC), has yielded divergent results and effects on mood which seem to be oppositely lateralized between these two groups. The inconsistent results that have been reported might be explained by methodological heterogeneity and drawbacks. METHODS: In this sham-controlled, single blind, crossover study, we tried to reproduce previous HF-rTMS findings of a negative mood induction in 28 healthy female subjects. To exclude individual anatomical differences, the left DLPFC was localised under magnetic resonance guidance (MRI). Mood assessment was performed before and just after HF-rTMS with Visual Analogue Scales and the Profile of Mood States. To detect possible delayed mood changes, ratings were also performed 30 min post HF-rTMS. RESULTS: We were unable to demonstrate significant mood changes from baseline after one single active HF-rTMS session on the left DLPFC. CONCLUSIONS: Although this study controlled for several methodological problems, the hypothesis that one single session of HF-rTMS on the left DLPFC has negative mood effects in healthy female volunteers was not supported.

Adult↗
PubMed2002

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.

Agomelatine (S 20098) has a unique and new pharmacological profile. It is a melatoninergic agonist and selective antagonist of 5-HT2C receptors, and has been shown to be active in several animal models of depression. The aim of this study was to determine the active dose of agomelatine in the treatment of major depressive disorder (DSM-IV criteria). The methodology used was a conventional double-blind design comparing three different doses of agomelatine (1, 5 and 25 mg once a day) with placebo over an 8-week treatment period. Paroxetine was used as the study validator. Seven hundred and eleven patients with a baseline mean score of 27.4 on the 17-item Hamilton Rating Scale for Depression (HAM-D) were included. On the pivotal analysis, the mean final HAM-D total score (Full Analysis Set LOCF) demonstrated agomelatine 25 mg to be statistically more effective than placebo. This was confirmed by other analyses and criteria (responders, remission, subpopulation of severely depressed patients, Montgomery-Asberg Depression Rating Scale, Clinical Global Impression-Severity of Illness). Agomelatine 25 mg alleviated the anxiety associated with depression, as measured on Hamilton Anxiety Scale. Paroxetine was found to be effective on pivotal analysis and most of the secondary criteria used to validate the study methodology and population. Agomelatine, whatever the dose, showed good acceptability with a side-effects profile close to that of placebo. In conclusion, this study demonstrates that agomelatine is efficient in the treatment of major depressive disorder and that 25 mg is the target dose.

Acetamides↗
PubMed1998

123I-5-I-R91150, a new single-photon emission tomography ligand for 5-HT2A receptors: influence of age and gender in healthy subjects.

5-HT2A receptors have been implicated in the pathophysiology of mood disorders and in the therapeutic effect of the so-called atypical antipsychotics. Recently, a new radioiodinated ligand with high affinity and selectivity for serotonin 5-HT2A receptors, 123iodinated 4-amino-N-1-[3-(4-fluorophenoxy)propyl]-4-methyl-4-piperidinyl] 5-iodo-2-methoxybenzamide (123I-5-I-R91150), has been developed and has been shown to be suitable for single-photon emission tomography (SPET) imaging. In this study the influence of age and gender on the ligand binding was investigated in normal volunteers. One hundred and fifty MBq of 123I-5-I-R91150 was administered to 26 normal volunteers (13 females and 13 males) with an age range of 23-60 years. SPET imaging was performed with a triple-headed gamma camera. For semi-quantitative analysis, ratios of ligand binding in different regions of interest to the binding in the cerebellum were calculated. Mean ratios of 1.7 were obtained. No gender difference was demonstrated. 5-HT2A binding was shown to decline with age. Over an age range of 40 years a reduction in ligand binding of 42% +/- 7% was found. These results are in agreement w in vitro and positron emission tomography findings of a decline in 5-HT2A receptor binding with age. The findings confirm the suitability of 123I-5-I-R91150 for SPET imaging of 5-HT2A receptors, and highlight the necessity for age-matched controls in clinical studies.

Adult↗
PubMed1997

Cerebral blood flow related to induction of a depressed mood within and out of the realm of attention in normal volunteers.

The effects of a depressed mood on regional cerebral blood flow (rCBF) were measured after a mood-induction procedure (MIP) in normal volunteers. The MIPs were administered 'within the realm of attention' and 'out of the realm of attention'. A modified Velten procedure, which consisted of tape-recorded self-referent depressive statements, was used for mood induction. For the induction out of the realm of attention, a combination of dichotic listening and subliminal stimulation was used. A neutral induction procedure served as a control condition. CBF was measured with Tc-99m HMPAO single photon emission computed tomography (SPECT) with regard to 14 healthy female students. Scores on mood rating scales showed negative changes after both MIPs. Statistical analyses revealed lateralized changes in rCBF in the thalamus. Decreased thalamic CBF in the right hemisphere was demonstrated after both MIPs compared with the neutral induction condition. Moreover, hippocampal rCBF increased significantly, but only after induction out of the realm of attention. These findings suggest both hippocampal and thalamic involvement in the regulation of mood experience.

Adult↗
PubMed1992

SPECT imaging of serotonin2 receptors in depression.

Changes of serotonin2 (5HT2) receptors have been described in depression, and long-term antidepressant treatment has been shown to decrease the number of 5HT2 receptors. In this study, single photon emission computed tomography (SPECT), with 2-123I-ketanserin as a ligand, was used to investigate 5HT2 receptors in vivo in the brain of depressed patients and normal volunteers. A higher uptake of the tracer was observed in the parietal cortex of the patients, and there was a right greater than left asymmetry in the infero-frontal region of the depressed subjects and not in that of the control subjects. These findings could indicate changes in 5HT2 receptors in major depression.

Adolescent↗
PubMed1990

Predictive value of two endogenicity measures.

Endogenicity has been considered to have a major predictive value as to the therapeutic response to antidepressants. Two recently introduced measures of endogenicity (the Michigan Discriminant Index and the Hamilton Endogenomorphy Subscale) were investigated regarding their potential predictive value. It was concluded that, in a group of selected depressive patients, neither the Michigan Discriminant Index, nor the Hamilton Endogenomorphy Subscale, had a predictive value concerning short-term response to antidepressants.

Adult↗
PubMed1988

Platelet 3H-paroxetine binding in depressed patients.

Studies using 3H-imipramine binding in platelets as a means of exploring the serotonin transport system in depressed patients have produced inconsistent findings. For this reason, we studied 3H-paroxetine binding in platelets, because we believed it might provide a more reliable ligand for studying serotonin transport. Subjects were 23 depressive inpatients and 23 normal controls. No differences in the maximal number of binding sites (Bmax) or in the dissociation constant (Kd) were found between depressives and controls.

Adult↗